Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONARCH 2: Abemaciclib + Fulvestrant in HR+ HER2- Advanced Breast Cancer
2023-506781-30-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Abemaciclib + fulvestrant with Placebo + fulvestrant (2 arms). Primary endpoint: Progression-Free Survival. Planned start May 2024; status: authorised.
02
Drugs
abemaciclibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-506781-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506781-30-00.